257 related articles for article (PubMed ID: 10613596)
21. Phase I/II trial of carboplatin dose escalation in combination chemotherapy with etoposide, bleomycin and GM-CSF support for poor prognosis nonseminomatous germ cell tumors patients.
Tjulandin SA; Stenina MB; Sidorova NJ; Delgado FG; Sokolov AV; Molchanov GV; Ljubimova NV; Garin AM
Neoplasma; 1996; 43(5):347-52. PubMed ID: 8996556
[TBL] [Abstract][Full Text] [Related]
22. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.
Droz JP; Kramar A; Biron P; Pico JL; Kerbrat P; Pény J; Curé H; Chevreau C; Théodore C; Bouzy J; Culine S;
Eur Urol; 2007 Mar; 51(3):739-46; discussion 747-8. PubMed ID: 17084512
[TBL] [Abstract][Full Text] [Related]
23. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
[TBL] [Abstract][Full Text] [Related]
25. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
26. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
27. The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/CCG 8882).
Rescorla F; Billmire D; Stolar C; Vinocur C; Colombani P; Cullen J; Giller R; Cushing B; Lauer S; Davis M; Hawkins E; Shuster J; Krailo M
J Pediatr Surg; 2001 Jan; 36(1):12-7. PubMed ID: 11150431
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
[TBL] [Abstract][Full Text] [Related]
29. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
30. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
[TBL] [Abstract][Full Text] [Related]
31. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
[TBL] [Abstract][Full Text] [Related]
32. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
33. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.
Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D
Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477
[TBL] [Abstract][Full Text] [Related]
34. [High-dose chemotherapy with peripheral blood stem cell autotransplantation for patients with poor-risk testicular germ cell tumors--pilot study of the Japan Blood Cell Transplantation Study Group].
Nakagawa S; Miki T; Akaza H; Ozono S; Okano T; Sonoda Y; Tsukamoto T; Terachi T; Naito K; Naito S; Nishiyama T; Nonomura N; Hara I; Hoshi S; Yoshida O
Hinyokika Kiyo; 1999 Nov; 45(11):805-9. PubMed ID: 10637748
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
36. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
37. [Germ cell tumor].
Kasai M; Kiyama Y
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1749-55. PubMed ID: 7574805
[TBL] [Abstract][Full Text] [Related]
38. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
